Meeder Asset Management Inc Glycomimetics Inc Transaction History

Meeder Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$1.83 - $5.41 $1,480 - $4,376	-809 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$4.03 - $6.5 $11,179 - $18,031	-2,774 Reduced 77.42%	809 $4,000
Q3 2019 Oct 17, 2019	BUY	$2.8 - $12.85 $10,032 - $46,041	3,583 New	3,583 $16,000
Q1 2018 May 03, 2018	SELL	$16.06 - $25.35 $867 - $1,368	-54 Closed	0 $0
Q4 2017 Feb 02, 2018	SELL	$10.51 - $17.22 $525 - $861	-50 Reduced 48.08%	54 $1,000
Q3 2017 Oct 20, 2017	BUY	$10.14 - $14.85 $1,054 - $1,544	104	104 $1,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.